A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.
Advanced Malignant Tumors Lymphomas
BIOLOGICAL: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Dose Limiting Toxicity (DLT), .Day 1 - Day 21|Treatment-related Adverse Events (TRAEs), Day 1 - 90 days after last administration
PK parameters, The area under the curve (AUC), Up to 90 days post last dose|PK parameters, Maximum concentration (Cmax), Up to 90 days post last dose|PK parameters, Time at which maximum concentration (Tmax), Up to 90 days post last dose|PK parameters, The half-life (t1/2), Up to 90 days post last dose|Positive rate of ADA and Nab, Up to 90 days post last dose|Positive rate of Circulating Immune Complex, Through study completion, an average of 1 year
A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors